Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-11
2011-01-11
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C514S04400A
Reexamination Certificate
active
07868159
ABSTRACT:
The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.
REFERENCES:
patent: 4082735 (1978-04-01), Jones et al.
patent: 4082736 (1978-04-01), Jones et al.
patent: 4101536 (1978-07-01), Yamamura et al.
patent: 4185089 (1980-01-01), Derrien et al.
patent: 4235771 (1980-11-01), Adam et al.
patent: 4406890 (1983-09-01), Tarcsay et al.
patent: 4606918 (1986-08-01), Allison et al.
patent: 4683202 (1987-07-01), Mullis et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5023243 (1991-06-01), Tullis et al.
patent: 5168053 (1992-12-01), Altman et al.
patent: 5190931 (1993-03-01), Inouye
patent: 5199942 (1993-04-01), Gillis et al.
patent: 5350674 (1994-09-01), Boenisch et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5710123 (1998-01-01), Heavner et al.
patent: 5710129 (1998-01-01), Lynch et al.
patent: 5928906 (1999-07-01), Koster et al.
patent: 6326193 (2001-12-01), Liu et al.
patent: 6716422 (2004-04-01), Gajewski et al.
patent: 2003/0138413 (2003-07-01), Vicari et al.
patent: 2003/0171253 (2003-09-01), Ma et al.
patent: 2003/0175971 (2003-09-01), Linderman et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0147608 (2005-07-01), Ryo et al.
patent: 2006/0239971 (2006-10-01), Mohapatra
patent: WO 92/07065 (1992-04-01), None
patent: WO 94/07529 (1994-04-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/96584 (2001-12-01), None
Kundu et al. Enhancement of human immunodeficiency virus specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. PNAS Dec. 1992, vol. 89: 11204-11208.
Siegal et al. Induction of antitumor immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. British Journal of Haematology 2003, vol. 122: 911-914.
Akira, et al. Toll-like receptor signaling.Journal of Biological Chemistry, 278:38105-38108 (2003).
Brummelkamp, et al. Stable suppression of tumorigenicity by virus-mediated RNA interference.Cancer Cell, 2:243-247 (2002).
Matsuda, et al. SOCS-1 can suppress CD3 and Syk-mediated NF-AT activation in a non-lymphoid cell line.FEBS Letters, 472:235-240 (2000).
Rao, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines.Journal of Immunology, 156:3357-3365 (1996).
Schmidt, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.Blood, 102(2):571-576 (Jul. 15, 2003).
Yamamoto, et al. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor B2 subunit.Biochem and Biophys Res Comm, 31):1188-1193 (2003).
Agrwal et al., “Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation,”Tetrahedron Letters, vol. 28, pp. 3539-3542, 1987.
Akira et al., “Toll-like Receptor Signaling,”Nat. Rev. Immunol., vol. 4, pp. 499-511, 2004.
Alexander et al., “SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of the Cytokine,”Cell, vol. 98, pp. 597-608, 1999.
Alexander et al., “The Rol+e of Suppressors of Cytokine Signaling (SOCS) Proteins in Regulation of the Immune Response,”Annu. Rev. Immunol., vol. 22, pp. 503-529, 2004.
Allen et al., “Th1-Th2: Reliable Paradigm or Dangerous Dogma?”Immunol. Today, vol. 18, pp. 387-392, 1997.
Altschul, “Amino Acid Substitution Matrices from an Information Theoretic Perspective,”J. Mol. Biol., vol. 219, pp. 555-565, 1991.
Baetz et al., “Suppressor of Cytokine Signaling (SOCS) Proteins Indirectly Regulate Toll-like Receptor Signaling in Innate Immune Cells,”J. Biol. Chem., vol. 279, pp. 54708-54715, 2004.
Balazs et al., “Blood Dendriti Cells Interact with Splenic Marginal Zone B Cells to Initiate T-Independent Immune Responses,”Immunity, vol. 17, pp. 341-352, 2002.
Banchereau et al., “Dendritic Cells and the Control of Immunity,”Nature, vol. 392, pp. 245-252, 1998.
Banchereau et al., “Autoimmunity Through Cytokine-Induced Dendritic Cell Activation,”Immunity, vol. 20, pp. 539-550, 2004.
Barron et al., “Influence of Plasma Viremia on Defects in Number and Immunophenotype of Blood Dendritic Cel Subsets in Human Immunodeficiency Virus 1-Infected Individuals,”J. Infect. Dis., vol. 187, pp. 26-37, 2003.
Beutler et al., “Innate Immune Sensing and its Roots: The Story of Endotoxin,”Nat. Rev. Immunol., vol. 3, pp. 169-176, 2003.
Brummelkamp, et al., “A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,”Science, vol. 296, pp. 550-553, 2002.
Burton et al., “HIV Vaccine Design and the Neutralizing Antibody Problem,”Nat. Immunol., vol. 5, pp. 233-236, 2004.
Carbonneil et al., “Defective Dendritic Cell Function in HIV-Infected Patients Receiving Effective Highly Active Antiretroviral Therapy: Neutralization of IL-10 Production and Depletion of CD4+CD25+Cells Restore High Levels of HIV-Specific CD4+T Cell Responses Induced by Dendritic Cells Generated in the Presence of IFN-α1,”J. Immunol., vol. 172, pp. 7832-7840, 2004.
Cech et al., “RNA Catalysis by a Group 1 Ribozyme,”J. Biol. Chem., vol. 267, pp. 17479-17482, 1992.
Cech, “Ribozymes and their Medical Implications,”J. Amer. Med. Assn., vol. 260, pp. 3030-, 1988.
Chong et al., “Suppressor of Cytokine Signaling-1 is a Critical Regulator of Interleukin-7-Dependent CD8+T Cell Differentiation,”Immunity, vol. 18, pp. 475-487, 2003.
Colonna, “Can we Apply the TH1-TH2 Paradigm to all Lymphocytes?”Nat. Immunol., vol. 2, pp. 899-900, 2001.
Crespo et al., “Indirect Induction of Suppressor of Cytokine Signaling-1 in Macrophages Stimulated With Bacterial Lipopolysaccharide: Partial Role of Autocrine/Paracrine Interferon-A/B,”Biochem. J., vol. 349, pp. 99-104, 2000.
Curtsinger et al., “Signal 3 Determines Tolerance Versus Full Activation of Naïve CD8T Cells: Dissociating Proliferation and Development of Effector Function,”J. Exp. Med., vol. 197, pp. 1141-1151, 2003.
Dalpke et al., “Suppressors of Cytokine Signaling (SOCS)-1 and SOCS-3 are Induced by CpG-DNA and Modulate Cytokine Responses in APCs,”J. Immunol., vol. 166, pp. 7082-7089, 2001.
Darnell et al., “Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins,”Science, vol. 264, pp. 1415-1421, 1994.
Dubois et al., “Dendritic Cells Enhance Growth and Differentiation of CD40-Activated B Lymphocytes,”J. Exp. Med., vol. 185, pp. 941-951, 1997.
Dubois et al., “Critical Role of IL-12 in Dendritic Cell-Induced Differentiation of Naïve B Lymphocytes1,2,”J. Immunol., vol. 161, pp. 2223-2231, 1998.
Dustin et al., “The Immunological Synapse and the Actin Cytoskeleton: Molecular Hardware for T Cell Signaling,”Nat. Immunol,. vol. 1, pp. 23-29, 2000.
Eckstein, “Phosphorothioates in Molecular Biology,”Trends Biol. Sci., vol. 14, pp. 97-100, 1989.
Elbashir et al., “RNA Interference is Mediated by 21-and 22-Nucleotide RNAs,”Genes&Development, vol. 15, pp. 188-200, 2000.
Elbashir et al., “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature, vol. 411, pp. 494-498, 2001.
Eyles et al., “Negative Regulation of Interleukin-12 Signaling by Suppressor of Cytokine Signaling-1,”J. B
Chen Si-Yi
Evel-Kabler Kevin C.
Huang Xue F.
Sharabi Andrew
Song Xiaotong
Baylor College of Medicine
Chong Kimberly
Ewing James F.
Foley & Lardner LLP
LandOfFree
Modulation of negative immune regulators and applications... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of negative immune regulators and applications..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of negative immune regulators and applications... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731362